Pneumotox » Drug » Drug

Adalimumab

See also under anti-TNF-alpha / TNF alpha antagonists

Last update : 26/05/2012

Patterns

I.a Acute ILD

I.b Subacute ILD

I.g Pulmonary fibrosis

I.w Rapidly progressive pulmonary fibrosis

IV.a Bronchospasm - wheezing - asthma

V.m Pleuro-pericardial effusion (ANA-negative)

X.b Antiphospholipid antibody syndrome

X.k Sarcoid-like disease

XI.e Opportunistic pulmonary infection

XVII.e Pneumocystis jiroveci pneumonia

Legend Patterns
?

- I -
  Parenchymal lung disease
- - I.a Acute ILD
  - I.b Subacute ILD
  - I.c Eosinophilic pneumonia (PIE)
  - I.d Organizing pneumonia (OP)
  - I.e Acute eosinophilic pneumonia (AEP)
  - I.f Acute fibrinous organizing pneumonia (AFOP)
  - I.g Pulmonary fibrosis
  - I.h Subclinical ILD
  - I.i Diffuse pulmonary calcification
  - I.j Exogenous lipoid pneumonia
  - I.k Lung nodule or nodules
  - I.l Diffuse alveolar damage (DAD)
  - I.m ILD with a granulomatous component
  - I.n Pulmonary alveolar proteinosis (PAP)
  - I.o Localized pulmonary fibrosis
  - I.p Interstitial foreign body reaction/granulomas
  - I.q Pulmonary nodulosis
  - I.r Endogenous lipoid pneumonia (phospholipidosis)
  - I.s A mass or masses
  - I.t Pneumoconiosis-talcosis
  - I.u 'Recall' radiation pneumonitis
  - I.v Subclinical changes in PFTs
  - I.w Rapidly progressive pulmonary fibrosis
  - I.x Biapical fibrosis
  - I.y Progression or exacerbation of preexisting ILD or fibrosis
  - I.z Areas of consolidation
  - I.aa Deterioration of pulmonary LAMM
  - I.ab Radiation-induced lung injury (RILI)
  - I.ac Relapsing pneumonitis
- II -
  Pulmonary edema - ALI - ARDS
- - II.a Noncardiogenic pulmonary edema - NCPE
  - II.b ALI - ARDS
  - II.c ARDS and the hemolytic-uremic syndrome
  - II.d Cardiogenic pulmonary edema
  - II.e Transfusion-related ALI (TRALI)
  - II.f Isolated hypoxemia/arterial desaturation
  - II.g Negative pressure pulmonary edema
  - II.h Overload pulmonary edema
  - II.i Flash pulmonary edema
  - II.j Transient pulmonary opacities
  - II.k The ATRA syndrome
- III -
  Pulmonary hemorrhage
- - III.a Diffuse alveolar hemorrhage - DAH
  - III.b Pneumorenal syndrome
  - III.c Hemoptysis
  - III.d ANCA-associated DAH
  - III.e Pulmonary hematoma
- IV -
  Airway involvement
- - IV.a Bronchospasm - wheezing - asthma
  - IV.b Bronchospasm and angioedema
  - IV.c Obliterative bronchiolitis
  - IV.d Lone isolated cough
  - IV.e Acute violent coughing
  - IV.f Severe or catastrophic bronchospasm
  - IV.g Respiratory bronchiolitis ILD (RB-ILD)
  - IV.h Tracheobronchial necrosis
  - IV.i Foreign body bronchiolitis - Diffuse aspiration bronchiolitis
  - IV.j Calcification of cartilaginous rings
  - IV.k Bronchiectasis
  - IV.l Bronchial stump dehiscence
  - IV.m Bronchial stricture/stenosis
  - IV.n Obstructive airway dysfunction
  - IV.o Airway hyperresponsiveness
  - IV.p Thermal, chemical or caustic airway injury
  - IV.q Reactive airway dysfunction syndrome (RADS)
- V -
  Pleural and/or pericardial involvement
- - V.a Pleural effusion
  - V.b Eosinophilic pleural effusion
  - V.c Pleural thickening/fibrosis
  - V.d Drug-induced lupus with pleural/pericardial effusion
  - V.e Serosanguineous pleural effusion - Hemothorax
  - V.f Pneumothorax
  - V.g Effusions and the ovarian hyperstimulation syndrome (OHSS)
  - V.h Chylothorax
  - V.i Acute pleuropulmonary reaction
  - V.j Subpleural fat deposits
  - V.k Pleural calcifications
  - V.l Malignant mesothelioma
  - V.m Pleuro-pericardial effusion (ANA-negative)
  - V.n Bloody pericardial effusion - Hemopericardium
  - V.o Acute pleuric chest pain
  - V.p Pleuroparenchymal fibroelastosis
  - V.q Empyema
  - V.r Pleural mass or masses
  - V.s Polyserositis
- VI -
  Pulmonary vasculopathy
- - VI.a Pulmonary thromboembolism
  - VI.b Pulmonary arterial hypertension
  - VI.c Pulmonary veno-occlusive disease
  - VI.d Pulmonary vasculitis or capillaritis (w/wo ANCA)
  - VI.e Lipid/fat pulmonary embolism
  - VI.f The hemolytic-uremic syndrome
  - VI.g Foreign body pulmonary vasculopathy
  - VI.h Acrylic cement pulmonary embolism
  - VI.i Acute pulmonary hypertension
  - VI.j Mercury pulmonary embolism
  - VI.k Eosinophilic pulmonary vasculitis
  - VI.l Acute pulmonary vasoconstriction and consequent PHTn
  - VI.m Silicone pulmonary embolism
  - VI.n Crystal pulmonary embolism
  - VI.o Air embolism (RV - pulmonary circulation)
  - VI.p Angiomatoid pulmonary vasculopathy
  - VI.q Rebound pulmonary hypertension
  - VI.r Septic pulmonary emboli
  - VI.t Pulmonary artery aneurysm
  - VI.u Pulmonary microthrombi
  - VI.v Foreign body pulmonary embolism
- VII -
  Mediastinal involvement
- - VII.a Lymphadenopathy
  - VII.b Lymphadenopathy with reactive changes
  - VII.c Mediastinal lipomatosis
  - VII.d Fibrosing mediastinitis
  - VII.e Granulomatous lymphadenopathy
  - VII.f Enlarged thymus
  - VII.g Mediastinal bleeding/hemorrhage
  - VII.h Pneumomediastinum
  - VII.i Mediastinitis
  - VII.j Compression of mediastinal organs
  - VII.k Mediastinal infiltration
- VIII -
  Central/large airway involvement and/or closure
- - VIII.a Upper airway angioedema
  - VIII.b Airway hematoma
  - VIII.c UAO other than angioedema or hematoma
  - VIII.d Thermal, chemical or caustic airway injury
  - VIII.e Laryngospasm
  - VIII.f Central airway instability/malacia
  - VIII.g Tracheal narrowing - Sabre sheath trachea
  - VIII.h Vocal cord dysfunction, adduction or closure
  - VIII.i Midline facial destructive lesions
  - VIII.j Dysphonia
  - VIII.k Airway fire/explosion
  - VIII.k Submucosal tracheal bleeding
  - VIII.m Drug-associated airway foreign body
  - VIII.o Perforation of the nasal septum
  - VIII.q Acute tongue involvement
- IX -
  Neuromuscular involvement
- - IX.a Respiratory muscle weakness or paralysis
  - IX.b Respiratory dyskinesia
  - IX.c Chest wall/muscle rigidity
  - IX.d Ventilatory depression - Apnea
  - IX.e Disordered breathing during sleep
  - IX.f Hiccup
  - IX.g Myopathy of respiratory muscles
  - IX.h Isolated dyspnea
- X -
  Systemic reactions or conditions
- - X.a DRESS
  - X.b Antiphospholipid antibody syndrome
  - X.c Vascular/capillary leak syndrome
  - X.d Drug-induced lupus syndrome
  - X.e Autoimmunity
  - X.f Anaphylaxis
  - X.g Hypersensitivity reactions
  - X.h Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
  - X.i Immune reconstitution syndrome - IRS/IRCS
  - X.j Myopathy - Myositis
  - X.k Sarcoid-like disease
  - X.l Subclinical ANA
  - X.m Systemic vasculitis
  - X.n Tumor lysis syndrome
  - X.o Sweet syndrome
  - X.p Serum sickness-like reaction
  - X.q Systemic inflammatory response
  - X.r Fluid retention
  - X.s ANCA-related systemic disease/vasculitis
  - X.t Jarisch-Herxheimer reaction
  - X.u MOF/MODS
  - X.v Systemic eosinophilic syndrome
- XI -
  Miscellaneous
- - XI.a Cyanosis, low SpO2 and a normal measured PaO2
  - XI.b Acute non-pleuritic chest pain/tightness/pressure
  - XI.c Acute pleuritic chest pain
  - XI.d Metabolic acidosis
  - XI.e Opportunistic pulmonary infection
  - XI.f Opportunistic airway infection
  - XI.g Aspiration pneumonia
  - XI.h Addictive risk
  - XI.i Isolated hypercapnea
  - XI.j Vertebral compression fracture
  - XI.k Rib hypertrophy, periostitis
  - XI.l Pharmacobezoar
  - XI.m Pulmonary emphysema - Lung bullae
  - XI.n Neutropenia - Agranulocytosis
  - XI.o Cavitary pulmonary opacities
  - XI.p Pneumocystis jiroveci pneumonia
  - XI.q Pneumocystis jiroveci colonization
  - XI.r Death from inhalation of compound
  - XI.s Tumoral cavitation
  - XI.t Lung abscess or abscesses
  - XI.u Pseudocyanotic skin discoloration
  - XI.v Mycobacterial (M tuberculosis-NTM-BCG) intrathoracic disease
  - XI.w Chest deformity - Platythorax
  - XI.x Lung compression from ascites
  - XI.y Death from overdose
  - XI.z Cutaneous vasculopathy (occlusive or vasculitic)
  - XI.aa Basilar consolidation of the 'Fire-eater's lung'
  - XI.ab Yellow nail syndrome
  - XI.ac Chronic chest or musculoskeletal pain
  - XI.ad Rib fracture
  - XI.ae Esophageal tear/rupture: Boerhaave syndrome
  - XI.af Esophageal ulceration/stenosis/stricture
  - XI.ag Localized chest pain
  - XI.ah Superior vena cava syndrome
- XII -
  Heart/circulatory involvement
- - XII.a Left ventricular failure
  - XII.b Valvular heart disease
  - XII.c Pericardial effusion or tamponade
  - XII.d Myocarditis
  - XII.e Tako-tsubo cardiomyopathy
  - XII.f Cardiomyopathy
  - XII.g Acute coronary syndrome - Myocardial infarction
  - XII.h Eosinophilic myocarditis
  - XII.i Endocarditis
  - XII.j Myocardial stunning
  - XII.k Pericardial thickening/constriction
  - XII.l Arrhythmias - Dysrhythmias
  - XII.m Cardiopulmonary arrest
  - XII.n Hypotension, cardiovascular collapse, shock
  - XII.o Coronary artery disease
  - XII.p Long QT syndrome
  - XII.r Coarctation of the aorta (acquired)
  - XII.r Congestive heart failure
  - XII.s Heart block
  - XII.t 'Torsades de pointe'
  - XII.u Left atrial/ventricular thrombosis
  - XII.v Arterial hypotension
  - XII.w Hypertrophic cardiomyopathy
- XIII -
  Thoracic cancers and neoplasms
- - XIII.a Lung cancer and other thoracic tumors
  - XIII.b Lymphoproliferative chest disease
  - XIII.c Leukemia
  - XIII.d Malignant mesothelioma
- XIV -
  Hemoglobinopathy (acquired)
- - XIV.a Methemoglobinemia
  - XIV.b Sulfhemoglobinemia
  - XIV.c Carboxyhemoglobinemia
  - XIV.d Interference with COHb measurement
  - XIV.e Interference with SpO2 measurement
- XV -
  Pathology
- - XV.a Path: Cellular ILD - NSIP-cellular
  - XV.b Path: Eosinophilic pneumonia (subacute or acute)
  - XV.c Path: Organizing pneumonia-pattern
  - XV.d Path: Acute fibrinous organizing pneumonia, AFOP-pattern
  - XV.e Path: ILD with a granulomatous component
  - XV.f Path: Diffuse alveolar damage (DAD) - Hyaline membranes
  - XV.g Path: Diffuse alveolar hemorrhage (DAH)
  - XV.h Path: Pulmonary fibrosis (NSIP-fibrotic)
  - XV.i Path: A reactive alveolar or bronchiolar epithelium
  - XV.j Path: UIP-pattern
  - XV.k Path: DIP-pattern
  - XV.l Path: Unclassifiable pulmonary fibrosis
  - XV.m Path: Lymphoid hyperplasia, LIP-pattern
  - XV.n Path: PAP-pattern - secondary PAP
  - XV.o Path: Endogenous lipoid pneumonia: phospholipidosis
  - XV.p Path: Exogenous lipoid pneumonia
  - XV.q Path: Interstitial foreign body reaction and deposits
  - XV.r Path: Smudged geographic necrosis
  - XV.s Path: Pneumoconiosis, talcosis, talcoma
  - XV.t Path: Pulmonary amyloid deposits
  - XV.u Path: Crystal storage disease
  - XV.u Path: Diffuse pulmonary calcification
  - XV.u Path: Pulmonary edema
  - XV.v Path: Subacute/acute cellular bronchiolitis
  - XV.w Path: Respiratory bronchiolitis (RB-) ILD-pattern
  - XV.x Path: Obliterative broncholitis
  - XV.y Path: Foreign body bronchiolitis
  - XV.z Path: Pulmonary capillaritis
  - XV.aa Path: Pulmonary vasculitis other than capillaritis
  - XV.ab Path: Eosinophilic vasculitis
  - XV.ac Path: Fat embolism
  - XV.ad Path: Silicone in lung tissue or capillaries
  - XV.ae Path: Foreign body microangiopathy/vasculopathy
  - XV.af Path: Elemental mercury embolism
  - XV.ag Path: Cement embolism
  - XV.ah Path: Crystal pulmonary embolism
  - XV.ai Path: Venoocclusive disease (PVOD)
  - XV.aj Path: Pulmonary hypertension incl. angiomatoid vasculopathy
  - XV.ak Path: Pleuritis n.o.s.
  - XV.al Path: Eosinophilic pleuritis
  - XV.am Path: Pleural fibrosis
  - XV.an Path: Pleuroparenchymal fibroelastosis
  - XV.ao Path: Kayexalate lung
  - XV.ap Path: Alveolar carbonaceous deposits
  - XV.aq Path: Fire eater's lung
  - XV.ar Path: Pulmonary microvascular granulocyte sequestration
  - XV.as Path: Deterioration of pulmonary LAMM
  - XV.at Path: Textiloma - Gossypiboma
  - XV.au Path: Occlusive skin vasculopathy
  - XV.av Path: Siliconoma
  - XV.aw Path: Smoking-related interstitial fibrosis (SRIF)
  - XV.ax Path: Lymphadenopathy with reactive changes
  - XV.ay Path: Granulomatous lymphadenopathy
  - XV.az Path: Eosinophilic bronchiolitis
  - XV.ba Path: Opportunistic pulmonary infection
  - XV.bb Path: Bronchiolar vasculitis and necrosis
  - XV.bc Path: Interstitial pulmonary edema
  - XV.bd Path: Pulmonary necrotizing granulomas
  - XV.be Path: Tracheal or bronchial wall ulceration
  - XV.bf Path: Foreign body reaction in large airway wall
  - XV.bg Path: Giant-cell interstitial pneumonia (GIP)-pattern
- XVI -
  Imaging
- - XVI.a Imaging: Diffuse haze
  - XVI.b Imaging: Ground-glass opacities (GGO)
  - XVI.c Imaging: Mosaic pattern of attenuation
  - XVI.d Imaging: Batwing or butterfly pattern
  - XVI.e Imaging: Subpleural pulmonary opacities
  - XVI.f Imaging: Bibasilar opacities
  - XVI.g Imaging: Diffuse whiteout
  - XVI.h Imaging: Biapical or mid-lung opacities
  - XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution
  - XVI.j Imaging: Wandering pulmonary opacities
  - XVI.k Imaging: An area or areas of consolidation
  - XVI.l Imaging: Peribronchovascular consolidation
  - XVI.m Imaging: Interlobular septal thickening
  - XVI.n Imaging: Intralobular septal thickening - Crazy paving
  - XVI.o Imaging: Localized ground-glass
  - XVI.p Imaging: Reticulation
  - XVI.q Imaging: An IPF-like imaging pattern
  - XVI.r Imaging: Areas of involvement with low attenuation numbers
  - XVI.s Imaging: Areas of involvement with high attenuation numbers
  - XVI.u Imaging: Diffuse random micronodules
  - XVI.v Imaging: Diffuse centrilobular micronodules
  - XVI.w Imaging: Multiple lung nodules
  - XVI.x Imaging: Halo sign
  - XVI.y Imaging: Reversed halo (Atoll) sign
  - XVI.z Imaging: A large nodule, nodules or masses
  - XVI.aa Imaging: Nodules, mass or masses with a central area of low attenuation
  - XVI.ab Imaging: Cavitary lung nodules
  - XVI.ac Imaging: XXX
  - XVI.ad Imaging: A calcified mass or masses
  - XVI.ae Imaging: Progressive massive fibrosis (PMF)
  - XVI.af Imaging: Lung bullae or cysts
  - XVI.ag Imaging: Pulmonary emphysema
  - XVI.ah Imaging: Pneumatoceles
  - XVI.ai Imaging: A tree-in-bud pattern
  - XVI.aj Imaging: Bronchiectasis
  - XVI.ak Imaging: Calcification of cartilaginous rings
  - XVI.al Imaging: Bronchial wall thickening
  - XVI.am Imaging: XXX
  - XVI.an Imaging: Pleural effusion
  - XVI.ao Imaging: Massive pleural effusion
  - XVI.ap Imaging: Pleural thickening
  - XVI.aq Imaging: Pneumothorax
  - XVI.ar Imaging: Hydropneumothorax
  - XVI.as Imaging: Pleural mass or masses
  - XVI.at Imaging:
  - XVI.au Imaging:
  - XVI.av Imaging:
  - XVI.aw Imaging:
  - XVI.ax Imaging: Vasc
  - XVI.ay Imaging: Vasc
  - XVI.az Imaging: Vasc
  - XVI.ba Imaging:
  - XVI.bb Imaging: Pneumomediastinum
  - XVI.bc Imaging: Lymph node enlargement
  - XVI.bd Imaging:
  - XVI.be Imaging: Enlarged thoracic venous collaterals
- XVII -
  Infection
- - XVII.a Pneumonia n.o.s.
  - XVII.b Bacterial pneumonia
  - XVII.c Pulmonary aspergillosis
  - XVII.d Pneumocystis jiroveci colonization
  - XVII.e Pneumocystis jiroveci pneumonia
  - XVII.f Viral pneumonia
  - XVII.g Tuberculosis
  - XVII.h Pulmonary NTM infection
  - XVII.i BCG infection
  - XVII.j Pulmonary mucormycosis
  - XVII.k Bacterial colonization of the airways
  - XVII.l Fungal colonization of the airways
  - XVII.m Pseudomembranous Aspergillus tracheobronchitis
  - XVII.n Opportunistic pulmonary infections
- XVIII -
  Distinctive signs and/or symptoms: eye catchers
- - XVIII.a x
  - XVIII.b x
  - XVIII.c x
  - XVIII.d x
  - XVIII.e x
  - XVIII.f x
  - XVIII.g x
  - XVIII.h x
  - XVIII.j x
  - XVIII.k Eye-catcher: Multiple radiolucent balls
  - XVIII.l Eye-catcher: Tongue edema
  - XVIII.m Eye-catcher: Acrylic cement embolism
  - XVIII.n Eye-catcher: Lipiodol pulmonary embolism
- XIX -
  Cytology (BAL, pleural fluid, FNA)
- - XIX.a Cytology: Lymphocytic BAL pattern
  - XIX.b Cytology: Neutrophilic BAL pattern
  - XIX.c Cytology: Eosinophilic BAL pattern
  - XIX.d Cytology: Hemorrhagic BAL pattern
  - XIX.e Cytology: Stainable iron-laden macrophages in BALF
  - XIX.f Cytology: Foamy (phospholipidotic) macrophages (BALF, pleural fluid, FNA)
  - XIX.g Cytology: Atypical alveolar cells in BALF
  - XIX.h -
  - XIX.i Cytology: Multinucleated giant cells in BALF
  - XIX.j Free mineral oil in BALF
  - XIX.k Cytology: Talc crystals in macrophages or lying freely in BALF
- XX -
  Diagnostic criteria for DIRD

The Drug-Induced Respiratory Disease Website

Philippe Camus 2012- v2

Pascal Foucher - Philippe Camus 1997- v1

Department of Pulmonary Medicine and Intensive Care University Hospital Dijon France

Contribution: Ph Bonniaud, N Baudouin, A Fanton, C Camus, N Favrolt, M Guerriaud, L Jacquet

Adalimumab

Patterns

I.a Acute ILD

I.b Subacute ILD

I.g Pulmonary fibrosis

I.w Rapidly progressive pulmonary fibrosis

IV.a Bronchospasm - wheezing - asthma

V.m Pleuro-pericardial effusion (ANA-negative)

X.b Antiphospholipid antibody syndrome

X.k Sarcoid-like disease

XI.e Opportunistic pulmonary infection

XVII.e Pneumocystis jiroveci pneumonia

Search

See also

Note Legend
?

Legend Patterns
?

Latest news

Latest changelog

The Drug-Induced Respiratory Disease Website

Philippe Camus 2012- v2

Pascal Foucher - Philippe Camus 1997- v1

Department of Pulmonary Medicine and Intensive Care University Hospital Dijon France

Contribution: Ph Bonniaud, N Baudouin, A Fanton, C Camus, N Favrolt, M Guerriaud, L Jacquet

Patterns

Search

See also

Note Legend ?

Legend Patterns ?

Latest news

Latest changelog

Note Legend
?

Legend Patterns
?